Vopimetostat
TNG-462 is an orally active and selective PRMT5 inhibitor with anti-tumor activity against methylthioadenosine phosphorylase (MTAP) deficiency and/or methylthioadenosine (MTA) accumulation cancers[1][2].
Product Specifications
CAS Number
2760483-96-1
Product Name Alternative
TNG-462
UNSPSC
12352005
Target
Histone Methyltransferase
Type
Reference compound
Related Pathways
Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/tng-462.html
Purity
99.91
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
CCC1=CC(NC(C(N2[C@@H](C3=CC=C(SC(C4CCN(CC4)C)=N5)C5=C3)CC[C@@H](C2)C)=O)=O)=CN=C1N
Molecular Formula
C28H36N6O2S
Molecular Weight
520.69
References & Citations
[1]Briggs K, et al. TNG462 is a potential best-in-class MTA-cooperative PRMT5 inhibitor for the treatment of MTAP-deleted solid tumors[J]. Cancer Research, 2023, 83 (7_Supplement) : 4970-4970.|[2]Kevin M Cottrell, et al. Piperidin-1- yl-n-pyrydi ne-3-yl-2-oxoacet am ide derivatives useful for the treatment of mtap-deficient and/or mt a-accumulating cancers. Patent WO2022026892A1.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC040745-100 1x 100 µL
CD45 / LCA (2B11 + PD7/26), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC040460-100 1x 100 µL
CD44 Standard (156-3C11), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC470253-100 1x 100 µL
Cytokeratin, LMW (AE-1), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC042853-100 1x 100 µL
CD54 / ICAM-1 (15.2), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC942395-500 1x 500 µL
CD25/ IL2RA (Activated Lymphocyte Marker) (IL2RA/2395), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details